A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Pfizer
Merck Sharp & Dohme LLC
Canadian Cancer Trials Group
Providence Health & Services
National Cancer Institute (NCI)
Sun Yat-sen University
Alliance for Clinical Trials in Oncology
Jonsson Comprehensive Cancer Center
SCRI Development Innovations, LLC
Pfizer
Sun Yat-sen University
Sixth Affiliated Hospital, Sun Yat-sen University
Institut du Cancer de Montpellier - Val d'Aurelle
Universitätsmedizin Mannheim